Redeye provides an initial take following Neem’s Hill’s Q2 2026 report. Sales came in slightly below expectations, although the underlying business continues to develop positively. We expect to make some downward fine-tuning adjustments to our sales estimates; however, we do not anticipate any significant impact on our valuation and continue to see solid upside potential in the share.
LÄS MER
